Research analysts at Cantor Fitzgerald began coverage on shares of Metsera (NASDAQ:MTSR – Get Free Report) in a research report issued on Tuesday, Marketbeat.com reports. The firm set an “overweight” rating on the stock.
Other research analysts have also recently issued research reports about the stock. Guggenheim began coverage on shares of Metsera in a research note on Tuesday. They set a “buy” rating and a $56.00 price target on the stock. Bank of America initiated coverage on shares of Metsera in a research note on Tuesday. They set a “buy” rating and a $38.00 target price on the stock. Finally, Evercore ISI initiated coverage on shares of Metsera in a research note on Tuesday. They set an “outperform” rating on the stock.
Get Our Latest Analysis on MTSR
Metsera Trading Down 0.4 %
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
- Five stocks we like better than Metsera
- Why Invest in High-Yield Dividend Stocks?
- Buffett’s on the Sidelines – Should You Follow?
- What does consumer price index measure?
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
